The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways

Journal of Virology

Volumn 84, Issue 19, 2010, Pages 9995-10003

  Bandaranayake, Rajintha M ^a   Kolli, Madhavi ^a   King, Nancy M ^a   Nalivaika, Ellen A ^a   Heroux, Annie ^b   Kakizawa, Junko ^c   Sugiura, Wataru ^c,d   Schiffer, Celia A ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; NELFINAVIR; PROTEINASE; VIRUS ENZYME; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; P16 PROTEASE, HUMAN IMMUNODEFICIENCY VIRUS 1; SULFONAMIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; GENE REARRANGEMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CHEMICAL STRUCTURE; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; ENZYME ACTIVE SITE; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HUMAN; KINETICS; METABOLISM; MISSENSE MUTATION; MOLECULAR GENETICS; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY; THERMODYNAMICS; VIRUS GENE; X RAY CRYSTALLOGRAPHY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG RESISTANCE, VIRAL; GENES, VIRAL; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NELFINAVIR; POLYMORPHISM, GENETIC; PROTEIN CONFORMATION; SEQUENCE HOMOLOGY, AMINO ACID; SULFONAMIDES; THERMODYNAMICS;

EID: 77956820913     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00505-10     Document Type: Article

References (45)

1. Ariyoshi, K., M. Matsuda, H. Miura, S. Tateishi, K. Yamada, and W. Sugiura. 2003. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01-AE (subtype E) infection differ from subtype B infection. J. Acquir. Immune Defic. Syndr. 33:336-342.
2. Carr, J. K., M. O. Salminen, C. Koch, D. Gotte, A. W. Artenstein, P. A. Hegerich, D. St. Louis, D. S. Burke, and F. E. McCutchan. 1996. Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J. Virol. 70:5935-5943.
3. Clemente, J. C., R. M. Coman, M. M. Thiaville, L. K. Janka, J. A. Jeung, S. Nukoolkarn, L. Govindasamy, M. Agbandje-McKenna, R. McKenna, W. Leelamanit, M. M. Goodenow, and B. M. Dunn. 2006. Analysis of HIV-1 CRF-01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry 45:5468-5477.
4. Collaborative Computational Project, Number 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50:760-763.
5. Copeland, R. A. 1996. Enzymes: a practical introduction to structure, mechanism, and data analysis. Wiley-VCH, New York, NY.
6. DeLano, W. L. 2002. The PyMol molecular graphics system. DeLano Scientific, San Carlos, CA.
7. de Oliveira, T., S. Engelbrecht, E. Janse van Rensburg, M. Gordon, K. Bishop, J. zur Megede, S. W. Barnett, and S. Cassol. 2003. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J. Virol. 77:9422-9430.
8. Emsley, P., and K. Cowtan. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60:2126-2132.
9. Foulkes-Murzycki, J. E., W. R. Scott, and C. A. Schiffer. 2007. Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure 15:225-233.
10. Gao, F., D. L. Robertson, S. G. Morrison, H. Hui, S. Craig, J. Decker, P. N. Fultz, M. Girard, G. M. Shaw, B. H. Hahn, and P. M. Sharp. 1996. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin. J. Virol. 70:7013-7029.
11. Geretti, A. M. 2006. HIV-1 subtypes: epidemiology and significance for HIV management. Curr. Opin. Infect. Dis. 19:1-7.
12. Gomes, P., I. Diogo, M. F. Gonçalves, P. Carvalho, J. Cabanas, M. C. Lobo, and R. Camacho. 2002. Different pathways to nelfinavir genotypic resistance in HIV-1 subtypes B and G. Conference on Retroviruses and Opportunistic Infections, abstract 46. Conference on Retroviruses and Opportunistic Infections, Seattle, WA.
13. Grossman, Z., E. E. Paxinos, D. Averbuch, S. Maayan, N. T. Parkin, D. Engelhard, M. Lorber, V. Istomin, Y. Shaked, E. Mendelson, D. Ram, C. J. Petropoulos, and J. M. Schapiro. 2004. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir. Antimicrob. Agents Chemother. 48:2159-2165.
14. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287.
15. Hemelaar, J., E. Gouws, P. D. Ghys, and S. Osmanov. 2006. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 20:W13-23.
16. Hu, D. J., A. Buve, J. Baggs, G. van der Groen, and T. J. Dondero. 1999. What role does HIV-1 subtype play in transmission and pathogenesis?: an epidemiological perspective. AIDS 13:873-881.
17. Kaleebu, P., N. French, C. Mahe, D. Yirrell, C. Watera, F. Lyagoba, J. Nakiyingi, A. Rutebemberwa, D. Morgan, J. Weber, C. Gilks, and J. Whitworth. 2002. Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda. J. Infect. Dis. 185:1244-1250.
18. Kanki, P. J., D. J. Hamel, J. L. Sankale, C. Hsieh, I. Thior, F. Barin, S. A. Woodcock, A. Gueye-Ndiaye, E. Zhang, M. Montano, T. Siby, R. Marlink, I. NDoi, M. E. Essex, and S. MBoup. 1999. Human immunodeficiency virus type 1 subtypes differ in disease progression. J. Infect. Dis. 179:68-73.
19. Kantor, R., D. A. Katzenstein, B. Efron, A. P. Carvalho, B. Wynhoven, P. Cane, J. Clarke, S. Sirivichayakul, M. A. Soares, J. Snoeck, C. Pillay, H. Rudich, R. Rodrigues, A. Holguin, K. Ariyoshi, M. B. Bouzas, P. Cahn, W. Sugiura, V. Soriano, L. F. Brigido, Z. Grossman, L. Morris, A. M. Vandamme, A. Tanuri, P. Phanuphak, J. N. Weber, D. Pillay, P. R. Harrigan, R. Camacho, J. M. Schapiro, and R. W. Shafer. 2005. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2:e112.
20. King, N. M., L. Melnick, M. Prabu-Jeyabalan, E. A. Nalivaika, S.-S. Yang, Y. Gao, X. Nie, C. Zepp, D. L. Heefner, and C. A. Schiffer. 2002. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease. Protein Sci. 11:418-429.
21. King, N. M., M. Prabu-Jeyabalan, P. Wigerinck, M.-P. de Béthune, and C. A. Schiffer. 2004. Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor. J. Virol. 78:12012-12021.
22. Kolli, M., S. Lastere, and C. A. Schiffer. 2006. Co-evolution of nelfinavirresistant HIV-1 protease and the p1-p6 substrate. Virology 347:405-409.
23. Kolli, M., E. Stawiski, C. Chappey, and C. A. Schiffer. 2009. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J. Virol. 83:11027-11042.
24. Masquelier, B., K. L. Assoumou, D. Descamps, L. Bocket, J. Cottalorda, A. Ruffault, A. G. Marcelin, L. Morand-Joubert, C. Tamalet, C. Charpentier, G. Peytavin, Z. Antoun, F. Brun-Vezinet, and D. Costagliola. 2008. Clinically validated mutation scores for HIV-1 resistance to fosamprenavir/ritonavir. J. Antimicrob. Chemother. 61:1362-1368.
25. Murphy, E., B. Korber, M. C. Georges-Courbot, B. You, A. Pinter, D. Cook, M. P. Kieny, A. Georges, C. Mathiot, F. Barre-Sinoussi, et al. 1993. Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the Central African Republic. AIDS Res. Hum. Retroviruses 9:997-1006.
26. Nunez, M., C. de Mendoza, L. Valer, E. Casas, S. Lopez-Calvo, A. Castro, B. Roson, D. Podzamczer, A. Rubio, J. Berenguer, and V. Soriano. 2002. Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations. Med. Sci. Monit 8:CR620-CR623.
27. Ode, H., S. Matsuyama, M. Hata, T. Hoshino, J. Kakizawa, and W. Sugiura. 2007. Mechanism of drug resistance due to N88S in CRF01-AE HIV-1 protease, analyzed by molecular dynamics simulations. J. Med. Chem. 50:1768-1777.
28. Ode, H., M. Ota, S. Neya, M. Hata, W. Sugiura, and T. Hoshino. 2005. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases. J. Phys. Chem. B 109:565-574.
29. Otwinowski, Z., and W. Minor. 1997. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:307-326.
30. Painter, J., and E. A. Merritt. 2006. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62:439-450.
31. Parkin, N., E. Stawiski, C. Chappey, and E. Coakley. 2007. Darunavir/amprenavir cross-resistance in clinical samples submitted for phenotype/genotype combination resistance testing. Conference on Retroviruses and Opportunistic Infections, abstract 607. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA.
32. Plantier, J. C., M. Leoz, J. E. Dickerson, F. De Oliveira, F. Cordonnier, V. Lemee, F. Damond, D. L. Robertson, and F. Simon. 2009. A new human immunodeficiency virus derived from gorillas. Nat. Med. 15:871-872.
33. Poveda, E., C. de Mendoza, L. Martin-Carbonero, A. Corral, V. Briz, J. Gonzalez-Lahoz, and V. Soriano. 2007. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. J. Antimicrob. Chemother. 60:885-888.
34. Prabu-Jeyabalan, M., E. Nalivaika, N. M. King, and C. A. Schiffer. 2004. Structural basis for coevolution of the human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 78:12446-12454.
35. Prabu-Jeyabalan, M., E. A. Nalivaika, K. Romano, and C. A. Schiffer. 2006. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. J. Virol. 80:3607-3616.
36. Prabu-Jeyabalan, M., E. A. Nalivaika, and C. A. Schiffer. 2002. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure 10:369-381.
37. Robertson, D. L., J. P. Anderson, J. A. Bradac, J. K. Carr, B. Foley, R. K. Funkhouser, F. Gao, B. H. Hahn, M. L. Kalish, C. Kuiken, G. H. Learn, T. Leitner, F. McCutchan, S. Osmanov, M. Peeters, D. Pieniazek, M. Salminen, P. M. Sharp, S. Wolinsky, and B. Korber. 2000. HIV-1 nomenclature proposal. Science 288:55-56.
38. Rose, J. R., R. Salto, and C. S. Craik. 1993. Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions. J. Biol. Chem. 268:11939-11945.
39. Spira, S., M. A. Wainberg, H. Loemba, D. Turner, and B. G. Brenner. 2003. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J. Antimicrob. Chemother. 51:229-240.
40. Surleraux, D. L., A. Tahri, W. G. Verschueren, G. M. Pille, H. A. de Kock, T. H. Jonckers, A. Peeters, S. De Meyer, H. Azijn, R. Pauwels, M. P. de Bethune, N. M. King, M. Prabu-Jeyabalan, C. A. Schiffer, and P. B. Wigerinck. 2005. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor. J. Med. Chem. 48:1813-1822.
41. Tebit, D. M., I. Nankya, E. J. Arts, and Y. Gao. 2007. HIV diversity, recombination and disease progression: how does fitness "fit" into the puzzle? AIDS Rev. 9:75-87.
42. Velazquez-Campoy, A., M. J. Todd, S. Vega, and E. Freire. 2001. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc. Natl. Acad. Sci. U. S. A. 98:6062-6067.
43. Velazquez-Campoy, A., S. Vega, E. Fleming, U. Bacha, Y. Sayed, H. W. Dirr, and E. Freire. 2003. Protease inhibition in African subtypes of HIV-1. AIDS Rev. 5:165-171. (Pubitemid 37336633)
44. Williams, T., and C. Kelley. Accessed 28 January 2009. gnuplot, version 4.2. http://www.gnuplot.info/.
45. Ziermann, R., K. Limoli, K. Das, E. Arnold, C. J. Petropoulos, and N. T. Parkin. 2000. A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir. J. Virol. 74:4414-4419.